Japanese Patients with Severe Asthma Identified as Responders to Omalizumab Treatment at 2 Years Based on the GETE Score Continued Treatment for an Extended Period
In this retrospective study the GETE after 2 years of omalizumab therapy emerged as the most meaningful predictor of the long-term effectiveness of omalizumab treatment in patients with severe asthma, highlighting the benefits of prolonged therapy in certain populations. These findings may guide future therapeutic strategies for severe asthma.
Authors
- Tetsutaro Nagaoka (ORCID: https://orcid.org/0000-0003-3578-3351)
- Tomohito Takeshige
- Yuuki Sandhu (ORCID: https://orcid.org/0009-0002-1388-3693)
- Hitoshi Sasano
- Ryo Atsuta (ORCID: https://orcid.org/0000-0002-4067-6019)
- Sonoko Harada (ORCID: https://orcid.org/0000-0002-3857-2624)
- Yuki Tanabe (ORCID: https://orcid.org/0000-0003-1463-2749)
- Jun Ito (ORCID: https://orcid.org/0000-0002-8883-2623)
- Norihiro Harada (ORCID: https://orcid.org/0000-0002-0962-5731)
- Kazuhisa Takahashi (ORCID: https://orcid.org/0000-0001-5749-4118)
- Shoko Ueda (ORCID: https://orcid.org/0000-0002-3263-1312)
- Kei Matsuno (ORCID: https://orcid.org/0009-0007-7536-0763)
- Sumiko Abe (ORCID: https://orcid.org/0000-0003-4746-0832)
- Ai Goto
Institutions
- Juntendo University (JP)
Publication Details
- Journal
- Journal of Asthma and Allergy
- Published
- 2024-11-01
- DOI
- https://doi.org/10.2147/jaa.s423256
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Abbott Japan
- Asahi Kasei Pharma Corporation
- Boehringer Ingelheim Japan
- Nippon Shinyaku
- Nipro
- Shionogi
- Kao Corporation
- Chugai Pharmaceutical
- Bayer Yakuhin
- Daiichi Sankyo Europe